Accendra Health

ACH

Market cap $237M

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced that it has commenced an offer to exchange (the “Exchange Offers”) any and all of the Company's outstanding 4.500% Senior Notes due 2029 (the “2029 Notes”) and 6.625% Senior Notes due 2030 (the “2030 Notes” and, together with the 2029 Notes, the “Existing Notes”). Eligible Holders of 2029 Notes that participate in the New Money Notes Issuance (as defined below) will be able to exchange such 2029 No.

Accendra Health, Inc. (ACH) Shareholder/Analyst Call Prepared Remarks Transcript

Accendra Health, Inc. is undergoing a multiyear turnaround, focusing on at-home medicine after divesting its hospital supply unit and cleaning up its balance sheet. ACH's recent refinancing extends maturities, reduces gross debt by ~$100 million, and provides a liquidity runway, enhancing the probability of successful long-term deleveraging. Management reaffirmed full-year guidance, but ongoing margin pressure and slow volume growth mean EBITDA will likely be at the lower end of the outlook.

Accendra Health, Inc. (ACH) Q1 2026 Earnings Call Transcript

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) today reported financial results for the first quarter ended March 31, 2026, and announced a more than $1.5 billion comprehensive balance sheet optimization transaction with commitments from existing creditors that will strengthen the balance sheet, significantly extend maturities and reduce total leverage. Unless otherwise noted, the results herein reflect the Company's continuing operations, which represent what was previously.

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) plans to release financial results for the first quarter of 2026 on Monday, May 11, 2026, before trading begins on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 8:30 a.m. EDT on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917.

Investors need to pay close attention to Accendra Health stock based on the movements in the options market lately.

Accendra Health is upgraded to "Buy" after severe underperformance, trading at just 2x 2027 free cash flow. ACH faces significant margin pressure and a challenging balance sheet, with net leverage expected at 4.9-5x by end-2026. 2026 is likely a trough year due to a major contract loss; growth is expected to resume in 2027, aided by UnitedHealth volumes.

Accendra Health, Inc. (ACH) Q4 2025 Earnings Call Transcript

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) today reported financial results for the fourth quarter ended December 31, 2025. Unless otherwise noted, the results herein reflect the Company's continuing operations, which primarily represent what was previously the Patient Direct segment and certain functional operations. “We ended the fourth quarter with the completion of the sale of the Products & Healthcare Services (P&HS) business on December 31, 2025, and we are.